{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-385430","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-09-08T22:05:32+00:00","discovered_at":"2026-09-09T10:05:00.560667+00:00","generated_at":"2026-09-09T10:05:31.981522+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evommune's EVO756 Phase 2b fails in atopic dermatitis; AD program halted","bullets":["Phase 2b trial of EVO756 in 121 adults with moderate-to-severe AD missed primary and secondary endpoints at all doses.","Company will cease EVO756 development for AD; will continue evaluation in migraine prophylaxis.","EVO301 (IL-18BP fusion protein) becomes lead AD program; Phase 2b planned for mid-2027 after positive Phase 2a data.","Cash, equivalents, and investments expected to fund operations into 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-385430","json":"https://secwatch.observer/filing/0001193125-26-385430.json","markdown":"https://secwatch.observer/filing/0001193125-26-385430.md","text":"https://secwatch.observer/filing/0001193125-26-385430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/0001193125-26-385430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T10:05:31.981522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}